Spyre Therapeutics, Inc. – NASDAQ:SYRE
Spyre Therapeutics stock price today
$16.11
-7.56
-31.94%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 1 day
Spyre Therapeutics stock price monthly change
-20.25%
month
Spyre Therapeutics stock price quarterly change
-20.25%
quarter
Spyre Therapeutics key metrics
Market Cap | 1.36B |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | -71.38 |
Revenue | N/A |
EBITDA | 40.31M |
Income | -364.22M |
Revenue Q/Q | -100% |
Revenue Y/Y | 48.49% |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeSpyre Therapeutics stock price history
Spyre Therapeutics stock forecast
Spyre Therapeutics financial statements
Average Price Target
$53.67
Potential upside: 233.12%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 688K | -217.08M | -31552.47% |
|---|---|---|---|
| Sep 2023 | 0 | -40.10M | |
| Dec 2023 | 1.04M | -63.18M | -6063.34% |
| Mar 2024 | 0 | -43.85M |
| Jun 2023 | 243529000 | 450.89M | 185.15% |
|---|---|---|---|
| Sep 2023 | 207265000 | 452.66M | 218.4% |
| Dec 2023 | 341859000 | 157.84M | 46.17% |
| Mar 2024 | 487602000 | 335.33M | 68.77% |
| Jun 2023 | -16.64M | 6.76M | 209.99M |
|---|---|---|---|
| Sep 2023 | -34.59M | -97.63M | -12.53M |
| Dec 2023 | -31.03M | -35.27M | 163.60M |
| Mar 2024 | -28.54M | -104.96M | 172.16M |
Spyre Therapeutics alternative data
| Feb 2024 | 69 |
|---|---|
| Mar 2024 | 30 |
| Apr 2024 | 30 |
| Jun 2024 | 30 |
| Jul 2024 | 30 |
Spyre Therapeutics other data
What is insider trading?
| Period | Buy | Sel |
|---|
-
What's the price of Spyre Therapeutics stock today?
One share of Spyre Therapeutics stock can currently be purchased for approximately $16.11.
-
When is Spyre Therapeutics's next earnings date?
Unfortunately, Spyre Therapeutics's (SYRE) next earnings date is currently unknown.
-
Does Spyre Therapeutics pay dividends?
No, Spyre Therapeutics does not pay dividends.
-
How much money does Spyre Therapeutics make?
Spyre Therapeutics has a market capitalization of 1.36B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 61.96% to 886K US dollars.
-
What is Spyre Therapeutics's stock symbol?
Spyre Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "SYRE".
-
What is Spyre Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Spyre Therapeutics?
Shares of Spyre Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Spyre Therapeutics have?
As Jul 2024, Spyre Therapeutics employs 30 workers.
-
When Spyre Therapeutics went public?
Spyre Therapeutics, Inc. is publicly traded company for more then 9 years since IPO on 7 Apr 2016.
-
What is Spyre Therapeutics's official website?
The official website for Spyre Therapeutics is spyre.com.
-
Where are Spyre Therapeutics's headquarters?
Spyre Therapeutics is headquartered at 221 Crescent Street, Waltham, MA.
-
How can i contact Spyre Therapeutics?
Spyre Therapeutics's mailing address is 221 Crescent Street, Waltham, MA and company can be reached via phone at +61 76515940.
-
What is Spyre Therapeutics stock forecast & price target?
Based on 3 Wall Street analysts` predicted price targets for Spyre Therapeutics in the last 12 months, the avarage price target is $53.67. The average price target represents a 233.12% change from the last price of $16.11.
Spyre Therapeutics company profile:
Spyre Therapeutics, Inc.
spyre.comExchange:
NASDAQ
Full time employees:
30
Industry:
Biotechnology
Sector:
Healthcare
Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.
221 Crescent Street
Waltham, MA 02453
Waltham, MA 02453
CIK: 0001636282
ISIN: US00773J2024
CUSIP: 00773J202
